So what's gonna happen now?

Market mechanics check on $GRRR ahead of Oct 15 ​1. $8.50 level reflects the $8 floor in the July $125M convertible bond 2. Downward pressure= bondholders shorthedging ahead of the SEC filing, NOT share dumping 3. Oct 15 is SEC paperwork, not news. Focus stays on Q4 GPU delivery

Scammer @TheLongInvest told people to buy $GRRR, Palladium, $GRAB, $WYFI, $NVO, $PYPL, $ASTS, $ONDS, $RR, $SIDU, $ADUR . All down big time from his buys and he stopped talking about them

Worst stock I ever bought $GRRR

I'm selling everything and going cash. That's too hard to keep holding $GRRR $ASTS

$GRRR Floor Reality Check ​At ~$11.17 ($307M cap), key floors: ​🔹 $8.50–$9.50 (~$230M–$260M cap): 52-wk low re-test (<1.2x '26E sales). 🔹 $5.00–$6.50 (~$140M–$180M cap): Tangible asset/cash floor. ​H2 '26 GPU delivery & $200M rev target remain key catalysts.

TLI is suddenly silent about $grrr. Only talks about stocks when they go up

$HIMS keeps splitting the room: nearly 3 million subscribers and fresh clinical hires in the UK and Australia, but FTC and state complaints plus a November class action deadline keep the tape heavy. $32 target hangs above a $29 stock.

$ASTS posted its worst week in over a month after B. Riley cut it to Neutral, flagging pricing pressure and launch delays. Three more BlueBirds are en route to Cape Canaveral and a Google Fi vet just took the commercial seat. Tug of war around $58 into next week.

$GRRR quietly stacked analyst wins this week: StoneX initiated with a Buy and a $25 target, then Benchmark lifted it to Strong Buy. Shares still sit near $13, holding under the 50-day average. Watching whether the bid sticks into next week.

Sold all stocks for cash

$HIMS near $30 as the class action pile-on grows, with KSF, Pomerantz and Hagens Berman all reminding investors of the Nov 2 lead plaintiff deadline. The FTC complaint over health data sharing is the overhang here until it clears.

$ASTS near $62 as a new change-of-control severance plan for execs fuels takeover chatter. No buyer named in the filing, so this is speculation doing the lifting. A fresh class action notice landed today too, keeping the legal overhang alive.

$GRRR StoneX just initiated on Gorilla with a Buy and $25 target while it trades near $14. Wall Street is waking up to the AI infrastructure story. $15 is the line in the sand.

$HIMS sinking premarket after pulling its $49 weight-loss pill copy under legal threats from Novo Nordisk, with a possible FDA probe on top. The FTC and class-action overhang isn't going away either. Revenue beat and raised guidance, but the market only hears the legal headlines.

$ASTS is having its best month since May. A new German filing put the 344-satellite BlueBird plan back in focus, but BlueBirds 14-16 still have no launch date. $61.88 is the near-term line to watch, the 2027 commercial-launch pushback remains the overhang

$GRRR closed the week higher at $14.01 after the Taiwan AI contract win (tens of millions, multi-year deal) and a first-ever Fitch rating (B-, positive outlook). H1 revenue nearly doubled and 2026 guidance was raised. Still a downtrend $14.61 is the resistance to watch

What the??????? He has to make this clear!!!!

It's worrying that $grrr still didn't announce an ER day. Sounds fishy no? @investingwithac